POLYHYDROXYALKANOATES FOR USE IN PREVENTION OF COLORECTAL CANCERS
A polyhydroxyalkanoate (PHA) for use in prevention of colorectal cancer (CRC) by oral administration can include: 3-hydroxybutyrate monomeric units. A method for prevention of CRC can include: orally administering to a subject an effective amount of PHA containing 3-hydroxybutyrate monomeric units. A method for prevention of CRC can include: orally administering to a subject a daily dosage of PHA containing 3-hydroxybutyrate monomeric units.
1 . A polyhydroxyalkanoate (PHA) for use in prevention of colorectal cancer (CRC) by oral administration, the PHA comprising:
3-hydroxybutyrate monomeric units.
2 . The PHA of claim 1 , wherein the PHA is a polyhydrobutyrate (PUB) homopolymer or a copolymer comprising at least 20% by mole of the 3-hydroxybutyrate monomeric units, the remainder being hydroxyalkanoate monomeric units different from the 3-hydroxybutyrate monomeric units.
3 . The PHA of claim 2 , wherein the PHA is poly-3-hydroxybutyrate (FHB).
4 . The PHA of claim 2 , wherein the hydroxyalkanoate monomeric units different from the 3-hydroxybutyrate monomeric units are selected from: 4-hydroxybutyrate, 3-hydroxyvalerate, 3-hydroxyhexanoate, 3-hydroxyoctanoate, 3-hydroxyundec-10-enoate, or 4-hydroxyvalerate.
5 . The PHA of claim 1 , wherein the PHA has a weight average molecular weight (M w ) greater than or equal to 5,000 daltons (Da) and less than or equal to 1,500,000 Da.
6 . The PHA of claim 1 , wherein the oral administration is an enteral administration to a subject that has a predisposition in developing CRC or has already shown at least one clinical symptom which is typical of an early stage of CRC.
7 . The PHA of claim 1 , wherein the oral administration is a dietary administration.
8 . The PHA of claim 6 , wherein the oral administration has a daily dosage greater than or equal to 0.3 grams per kilogram (g/kg) of body weight of the subject.
9 . The PHA of claim 6 , wherein the oral administration has a daily dosage less than or equal to 5.0 grams per kilogram (g/kg) of body weight of the subject.
10 . The PHA of claim 1 , wherein the PHA is poly-3-hydroxybutyrate (PHB).
11 . The PHA of claim 1 , wherein the PHA has a weight average molecular weight (M w ) greater than or equal to 100,000 daltons (Da) and less than or equal to 1,000,000 Da.
12 . The PHA of claim 1 , wherein the oral administration is an enteral administration to a subject that has a predisposition in developing CRC.
13 . The PHA of claim 1 , wherein the oral administration is an enteral administration to a subject that has already shown at least one clinical symptom which is typical of an early stage of CRC.
14 . The PHA of claim 6 , wherein the oral administration has a daily dosage greater than or equal to 0.5 grams per kilogram (g/kg) of body weight of the subject.
15 . A method for prevention of colorectal cancer (CRC), the method comprising:
orally administering to a subject an effective amount of polyhydroxyalkanoate (PHA) comprising 3-hydroxybutyrate monomeric units.
16 . A method for prevention of colorectal cancer (CRC), the method comprising:
orally administering to a subject a daily dosage of polyhydroxyalkanoate (PHA) comprising 3-hydroxybutyrate monomeric units.
17 . The method of claim 16 , wherein the daily dosage is greater than or equal to 0.3 grams per kilogram (g/kg) of body weight of the subject and is less than or equal to 5.0 g/kg of the body weight of the subject.
18 . The method of claim 16 , wherein the daily dosage is greater than or equal to 0.3 grams per kilogram (g/kg) of body weight of the subject and is less than or equal to 2.5 g/kg of the body weight of the subject.
19 . The method of claim 16 , wherein the daily dosage is greater than or equal to 0.5 grams per kilogram (g/kg) of body weight of the subject and is less than or equal to 5.0 g/kg of the body weight of the subject.
20 . The method of claim 16 , wherein the daily dosage is greater than or equal to 0.5 grams per kilogram (g/kg) of body weight of the subject and is less than or equal to 2.5 g/kg of the body weight of the subject.